+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Rare Disease Genetic Testing Market: Analysis and Forecast, 2023-2033

  • PDF Icon

    Report

  • 104 Pages
  • February 2024
  • Region: Asia Pacific
  • BIS Research
  • ID: 5914387
10% Free customization
Description Jump to:
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Asia-Pacific rare disease genetic testing market was valued at $0.58 billion in 2023 and is anticipated to reach $2.40 billion by 2033, witnessing a CAGR of 15.25% during the forecast period 2023-2033. Advanced technologies like whole-genome sequencing (WGS) and whole-exome sequencing (WES) analyze an individual's entire genetic code (genome) or specific protein-coding regions (exome), respectively. They aid in detecting genetic variations, mutations, or abnormalities linked to rare diseases.

Market Introduction

The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors. Increased awareness, advancements in genetic testing technologies, and rising healthcare expenditure contribute to market expansion. Moreover, the region's large population base and diverse genetic profiles present significant opportunities for genetic testing providers. Government initiatives aimed at improving healthcare infrastructure and expanding access to genetic testing services further propel market growth. Additionally, collaborations between healthcare organizations, research institutions, and industry players facilitate the development and adoption of innovative genetic testing solutions tailored to the region's specific needs. With a growing focus on precision medicine and personalized healthcare, the APAC rare disease genetic testing market is poised for continued expansion and innovation in the foreseeable future.

Market Segmentation:

Segmentation 1: by Disease Type

  • Gastroenterology Disease
  • Endocrine and Metabolism Disease
  • Cardiovascular Disease
  • Neurology Disease
  • Hematology and Oncology Disease
  • Dermatology Disease
  • Other Diseases

Segmentation 2: by Technology

  • Sanger Sequencing
  • PCR
  • NGS
  • Microarrays
  • Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Singapore
  • Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The APAC rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The APAC rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

  • 3billion, Inc.
  • Konica Minolta (Ambry Genetics, Inc.)
  • BGI Group
  • Strand Life Science Pvt Ltd.


This product will be delivered within 3-5 business days.

Table of Contents

Executive SummaryScope of the StudyResearch Methodology
1 Market
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.2.1 Inclusion Criteria
1.1.2.2 Exclusion Criteria
1.1.3 Market Overview
1.1.3.1 Market Footprint
1.1.3.2 Market Size and Future Growth Potential
1.1.4 COVID-19 Impact on the Market
1.1.4.1 Impact on Research and Clinical Operations
1.1.4.2 COVID-19 Impact: Current Scenario of the Market
1.2 Industry Analysis
1.2.1 Regulatory Framework
1.2.1.1 Legal Requirements and Framework in Asia-Pacific
1.2.1.1.1 Japan
1.2.1.1.2 China
1.2.1.1.3 India
1.2.1.1.4 Taiwan
1.2.2 Patent Analysis
1.2.2.1 Patent Filing Trend (by Country)
1.2.2.2 Patent Filing Trend (by Year)
1.2.3 Funding Scenario
1.3 Market Dynamics
1.3.1 Overview
1.3.2 Market Drivers
1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
1.3.3 Market Challenges
1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
1.3.4 Market Opportunities
1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies
2 Rare Disease Genetic Testing Market (by Region)
2.1 Asia-Pacific Rare Disease Genetic Testing Market
2.1.1 Market Dynamics
2.1.1.1 Impact Analysis
2.1.2 Market Size and Forecast
2.1.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
2.1.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
2.1.2.3.1 Japan
2.1.2.3.1.1 Market Dynamics
2.1.2.3.1.2 Market Size and Forecast
2.1.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.2 China
2.1.2.3.2.1 Market Dynamics
2.1.2.3.2.2 Market Size and Forecast
2.1.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.3 Australia
2.1.2.3.3.1 Market Dynamics
2.1.2.3.3.2 Market Size and Forecast
2.1.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.4 South Korea
2.1.2.3.4.1 Market Dynamics
2.1.2.3.4.2 Market Size and Forecast
2.1.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.5 India
2.1.2.3.5.1 Market Dynamics
2.1.2.3.5.2 Market Size and Forecast
2.1.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.6 Singapore
2.1.2.3.6.1 Market Dynamics
2.1.2.3.6.2 Market Size and Forecast
2.1.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
2.1.2.3.7 Rest-of-Asia-Pacific
2.1.2.3.7.1 Market Dynamics
2.1.2.3.7.2 Market Size and Forecast
2.1.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
2.1.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
3 Company Profiles
3.1 Overview
3.1.1 3billion, Inc.
3.1.1.1 Company Overview
3.1.1.2 Role of 3billion, Inc. in the Rare Disease Genetic Testing Market
3.1.1.3 Recent Developments
3.1.1.4 Analyst Perspective
3.1.2 Konica Minolta (Ambry Genetics, Inc.)
3.1.2.1 Company Overview
3.1.2.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Rare Disease Genetic Testing Market
3.1.2.3 Financials
3.1.2.4 Recent Developments
3.1.2.5 Analyst Perspective
3.1.3 BGI Group
3.1.3.1 Company Overview
3.1.3.2 Role of BGI Group in the Rare Disease Genetic Testing Market
3.1.3.3 Financials
3.1.3.4 Recent Developments
3.1.3.5 Analyst Perspective
3.1.4 Strand Life Science Pvt Ltd.
3.1.4.1 Company Overview
3.1.4.2 Role of Strand Life Science Pvt Ltd. in the Rare Disease Genetic Testing Market
3.1.4.3 Recent Developments
3.1.4.4 Analyst Perspective
List of Figures
Figure 1: Prevalence Rare Disease, 2022
Figure 2: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 3: Rare Disease Genetic Testing Market, Market Dynamics
Figure 4: Most Frequently Studied Rare Diseases, 2021
Figure 5: Asia-Pacific Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
Figure 6: Asia-Pacific Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
Figure 7: Share of Key Developments and Strategies, January 2019-June 2023
Figure 8: Rare Disease Genetic Testing Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Asia-Pacific Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
Figure 13: Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
Figure 14: Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
Figure 15: NIH Funding on Rare Diseases, $Million, 2013-2023
Figure 16: Rare Disease Genetic Testing Market Dynamics
Figure 17: Rare Disease Prevalence in India, 2022
Figure 18: Prevalence of Rare Diseases, 2022
Figure 19: Most Frequently Studied Rare Diseases, 2021
Figure 20: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
Figure 21: Rare Disease Genetic Testing Market Share (by Region), 2022-2033
Figure 22: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
Figure 23: Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 24: Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 25: Asia-Pacific Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
Figure 26: Japan Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 27: Japan Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 28: Japan Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 29: China Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 30: China Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 31: China Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 32: Australia Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 33: Australia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 34: Australia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 35: South Korea Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 36: South Korea Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 37: South Korea Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 38: India Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 39: India Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 40: India Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 41: Singapore Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 42: Singapore Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 43: Singapore Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 44: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market, $Million, 2022-2033
Figure 45: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
Figure 46: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
Figure 47: Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
Figure 48: 3billion, Inc: Product Portfolio
Figure 49: Konica Minolta (Ambry Genetics, Inc.): Product Portfolio
Figure 50: Konica Minolta (Ambry Genetics, Inc.).: Overall Financials, $Million, 2020-2022
Figure 51: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Segment), $Million, 2020-2022
Figure 52: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Region), $Million, 2020-2022
Figure 53: Konica Minolta (Ambry Genetics, Inc.): R&D Expenditure, $Million, 2020-2022
Figure 54: BGI Genomics: Product Portfolio
Figure 55: BGI Genomics.: Overall Financials, $Million, 2020-2022
Figure 56: Strand Life Science Pvt Ltd.: Product Portfolio
List of Tables
Table 1: Key Questions Answered in the Report
Table 2: Funding for Rare Disease Research
Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
Table 5: Asia-Pacific Rare Disease Genetic Testing Market, Impact Analysis

Executive Summary

The Asia-Pacific rare disease genetic testing market is estimated to reach $2.40 billion by 2033, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 15.25% during the forecast period 2023-2033.

The Asia-Pacific Rare Disease Genetic Testing Market: Drivers and Challenges

Market Drivers

  • Technological Advancements in Rare Disease Diagnostics
  • High Prevalence of Rare Diseases owing to the Large Population of Countries such as China and India
  • Government Initiatives to Support the Early Diagnosis of Rare Disease

Market Restraints

  • Difficulty in Diagnosis of Rare Diseases
  • Significant Capital Requirement for Research and Development
  • Lack of Awareness among Patients and Physicians Surrounding Rare Diseases

USPs of report

  • Vast segmentation of the report, especially the vast number of application types considered
  • Analysis of business drivers and challenges of the Asia-Pacific Rare Disease Genetic Testing Market
  • Detailed analysis of Rare Disease Genetic Testing Market for Japan, China, Australia, Singapore, and India

Analyst’s Perspective on Rare Disease Genetic Testing Market

The Principal Analyst states, 'Rapid technological advancements in rare disease genetic testing, rising prevalence of genetic disorders and congenital disorders, and growing recognition and emphasis on early detection and prevention of rare diseases in pediatric populations are expected to contribute to the market growth. The Asia-Pacific rare disease genetic testing market is expected to register significant growth during the forecast period 2023-2033.'

Some of the prominent names in this market are:

  • 3billion, Inc.
  • Konica Minolta (Ambry Genetics, Inc.)
  • BGI Group
  • Strand Life Science Pvt Ltd.

Key Questions Answered in the Report

  • What are the major market drivers, challenges, and opportunities in the Asia-Pacific rare disease genetic testing market?
  • What are the key development strategies implemented by the key players to stand out in the Asia-Pacific rare disease genetic testing market?
  • How is each segment of the rare disease genetic testing market expected to grow during the forecast period, and what revenue is expected to be generated by each of these segments by the end of 2033?
  • What is the market segmentation by technology? How are the technology types ranked in the rare disease genetic testing market?

Companies Mentioned

  • 3billion, Inc.
  • Konica Minolta (Ambry Genetics, Inc.)
  • BGI Group
  • Strand Life Science Pvt Ltd.

Table Information

Report AttributeDetails
No. of Pages104
PublishedFebruary 2024
Forecast Period2023 - 2033
Estimated Market Value ( USD ) in 2023 $ 0.58 Billion
Forecasted Market Value ( USD ) by 2033 $ 2.4 Billion
Compound Annual Growth Rate15.2%
Regions CoveredAsia Pacific
No. of Companies Mentioned4

Related Topics

Related Reports

Global Hereditary Genetic Testing Market: Focus on Product, Sample Type, Technology, Genetic Testing Type, Application Area, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033 - Product Image

Global Hereditary Genetic Testing Market: Focus on Product, Sample Type, Technology, Genetic Testing Type, Application Area, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033

  • Report
  • 113 Pages
  • Global
From
Asia-Pacific Genetic Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Asia-Pacific Genetic Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 75 Pages
  • Asia Pacific
From
Rare Disease Genetic Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029 - Product Image

Rare Disease Genetic Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • Report
  • 120 Pages
  • Global
From
Rare Disease Genetic Testing Market by Disease Type, Technology, Specialty, End-User - Global Forecast 2025-2030 - Product Image

Rare Disease Genetic Testing Market by Disease Type, Technology, Specialty, End-User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Genetic Testing Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis - Product Image

Genetic Testing Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis

  • Report
  • 260 Pages
  • Global
From

About the Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing market is a subset of the larger Genomics market. It focuses on the diagnosis and treatment of rare genetic diseases, which are caused by mutations in a single gene. These tests are used to identify the genetic cause of a disease, as well as to predict the risk of developing a disease in the future. They can also be used to identify the best treatment options for a particular patient. The Rare Disease Genetic Testing market is growing rapidly, driven by advances in technology and the increasing availability of genetic testing services. This has enabled more accurate diagnosis and treatment of rare diseases, as well as the development of new treatments. Companies in the Rare Disease Genetic Testing market include Ambry Genetics, Invitae, Counsyl, and GeneDx. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.